Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Use of Liraglutide (Victoza, Saxenda) & Semaglutide (Ozempic, Wegovy, Rybelsus) Comes with Risk of Gastrointestinal Disorders Use of Liraglutide (Victoza, Saxenda) & Semaglutide (Ozempic, Wegovy, Rybelsus) Tied to Increased Risk for Pancreatitis and Bowel Obstruction A new study showed that use of the GLP1 agonist medications approved for diabetes and weight loss including liraglutide (Victoza, Saxenda) & semaglutide (Ozempic, Wegovy, Rybelsus) come with a 9X increased risk of pancreatitis, 4X increased risk of bowel obstruction and 3.5X increased risk of gastroparesis compared to controls
"Important update: required documentation for select ePA requests." Confirms GLP-1 medications require attached documentation for ePA
FDA Drug Shortages Database
The date is written on the label
Most peptides are self-injected subcutaneously (under the skin) using a small insulin-type needle
If you believe that 1mg is too much for you, and you find that youre getting weight loss results at 0.5mg, then you should have a conversation with your prescriber to discuss reducing your weekly dose
